~~<i id='736240698F'><strike id='736240698F'><tt id='736240698F'><pre id='736240698F'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：focus 2025-09-06 06:44:28 Page View：8

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ASCO eve: Let’s set the table for this year's meeting
Next article： Supreme Court strikes down use of affirmative action

explore

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Delta passengers in Vegas fall sick while waiting on flight in triple

1:30InthisMarch4,2018,filephoto,aBoeing737jetliner,belongingtoDeltaAirlines,isshownonthetarmacMcCarr

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

A new ‘biological computer' targets cancer while sparing healthy cells

AdobeTheholygrailofcancerdrugtargetsisakintoaunicornhorn:amarkerthatonlycancercellshave,clearlydisti